Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.
Eluciderm Inc. has identified compounds acting as inhibitors of Wnt signaling and/or poly(ADP-ribose) polymerase tankyrase-2 (TNKS2; PARP5B) and/or poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) and/or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback